Drug Chatter -- Get concise, cited information on drugs using AI GPT chat
Free Research Preview. DrugChatter may produce inaccurate information.

Can you name the year sapropterin was approved?

See the DrugPatentWatch profile for sapropterin

When was sapropterin approved by the FDA?

Sapropterin received FDA approval in December 2007. It treats phenylketonuria (PKU), a metabolic disorder that keeps the body from processing phenylalanine.

How does sapropterin work against PKU?

The drug activates phenylalanine hydroxylase, the enzyme missing or defective in PKU patients. This restores partial enzyme activity and reduces blood phenylalanine levels.

What conditions does sapropterin treat beyond the initial indication?

FDA granted sapropterin an additional indication in 2019 for patients who respond to the drug and who are on a phenylalanine-restricted diet.

When does the sapropterin patent expire?

The basic compound patent expired in 2014. Current exclusivity for the dihydrochloride salt form held by BioMarin ended around 2021.



Other Questions About Sapropterin :

How was sapropterin's therapeutic potential identified? How does sapropterin dosage impact cognitive abilities? What key studies led to sapropterin s approval? Does regular sapropterin testing improve patient prognosis? Are there any cases where sapropterin fails to manage pku symptoms? Are there specific factors causing sapropterin failure in pku management? What role does sapropterin play in sustained pku treatment?